Table 8 (A) Quality of life of metastatic gastric cancer patients, (B) Median difference before–after of quality of Life
| Â | Mean (before) | Std. deviation | Std. error | P-value | Mean (after) | Std. deviation | Std. error | P-value |
|---|---|---|---|---|---|---|---|---|
(A) Quality of life in patients with metastatic gastric cancer | ||||||||
Global quality (BCc1 nanomedicine) | 48.88 | 13.614 | 2.779 | 0.118 | 45.63 | 11.009 | 2.247 | 0.200 |
Global quality (Placebo) | 47.16 | 13.280 | 3.047 | 0.200 | 51.58 | 12.384 | 2.841 | 0.200 |
| Â | Mean* | Std. deviation | Std. error mean | P-value |
|---|---|---|---|---|
(B) Median difference (before–after) of quality of life | ||||
Quality of BCc1 (before–after) | 3.250 | 8.975 | 1.832 | 0.089 |
Quality of Placebo (before–after) | − 4.421 | 6.947 | 1.594 | 0.013 |